Login

Laurus Labs Ltd.

₹580.0

Overview Charts Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Corp. Action Documents
Consolidated
Standalone

Laurus Labs Ltd.

₹580.0

₹580.0

-40.65 (-6.55%) - 4 Apr 2025 09:58 AM

About Company

Laurus Labs Limited offers broad and integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The company develops innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. It works with all the top generic pharmaceutical companies in the world. The company sells its APIs in many countries. Its major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. Continuous innovation is the lifeblood of its business. Therefore, it undertakes dedicated R&D in areas that have significant growth potential. The company has commercialised various products since inception across three distinct business units: Generics API, Generics FDF and Synthesis.

Market Cap. ₹33,469 Cr.
52 Week - High/Low ₹646/385
P/E Ratio 134.05
P/B Ratio 7.96
Enterprise Value ₹34,150 Cr.
ROE % 5.44
RSI Value -
EMA 50 600.14
EMA 200 599.22
Net Profit 224 Cr.
Net Profit 3year growth -76.6 Cr.
Net Profit 3 year (back) 956 Cr.
Debt to Equity 0.49 %
EPS Growth TTM 22.16 %
Current Ratio 1.22 %
100 Day SMA 570 Rs.
200 Day SMA 514 Rs.
21 Day SMA 589 Rs.
50 Day SMA 580 Rs.
Book Value 78 Rs.
EV/EBITDA Ratio 39
QoQ EPS Growth 35 %
QoQ Operating Profit Growth 13 %
QoQ Sales Growth 7 %
Sales Latest Quarter 1,265 Cr.
YoY Sales Growth 12 %
Market Cap. ₹33,469 Cr.
52 Week - High/Low ₹646/385
P/E Ratio 167.29
P/B Ratio 8.14
Enterprise Value ₹34,486 Cr.
ROE % 4.15
RSI Value -
EMA 50 600.14
EMA 200 599.22
Net Profit 158 Cr.
Net Profit 3year growth 8.35 Cr.
Net Profit 3 year (back) 984 Cr.
Debt to Equity 0.61 %
EPS Growth TTM 6.61 %
Current Ratio 1.23 %
100 Day SMA 570 Rs.
200 Day SMA 514 Rs.
21 Day SMA 589 Rs.
50 Day SMA 580 Rs.
Book Value 76 Rs.
EV/EBITDA Ratio 38
QoQ EPS Growth 365 %
QoQ Operating Profit Growth 59 %
QoQ Sales Growth 16 %
Sales Latest Quarter 1,415 Cr.
YoY Sales Growth 18 %
Add Parameters

Growth

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Yearly

Insight market
Terms | Privacy | Contact Us
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.